A Global,Phase 2,Randomized,Double-Blind,Placebo-Controlled,Response-Adaptive Dose-Ranging Study of BMS-986177,anOralFactorXIa Inhibitor,for the PreventionofNewIschemi Stroke or New Silent Brain Infarction in Patients ReceivingAspirin and clopidogre

Administered By

Awarded By

Contributors

Start/End

  • June 3, 2019 - November 22, 2021